Dobutamine is a Beta-1 agonist.

Indications for Use

Dobutamine is used to treat cardiogenic shock and severe heart failure to increase contractility and cardiac output. It is used for short term treatment with clients with severe systolic dysfunction who have low blood pressure and significantly reduced cardiac output. It is only used in critical care units.

Mechanism of Action

Dobutamine stimulates Beta-1 receptors to increase the force of contraction and conduction velocity. Beta 1 receptors are mostly in the cardiac muscle, so stimulation of these receptors will result in a flight-or-fight response of increased heart rate (minor effect), increased force of contraction and increased velocity of impulse contraction across the myocardium. The result is an improved cardiac output without an increased heart rate.

Nursing Considerations

Administration: IV infusion only, dilute concentration before administering. Large vein or central line infusion and only with infusion device.

Onset of action is 1-2 minutes and peak effect 10 minutes.  The duration of action is a minute, so dobutamine is administered by continuous infusion.

Assessment and Monitoring

• Continuously monitor electrocardiogram (ECG). Assess for premature ventricular contractions (PVC’S), increased heart rate
• Blood pressure q 15 minutes
• Cardiac output, PCWP (pulmonary capillary wedge pressure), CVP (central venous pressure)
• Monitor urine output to assess renal perfusion
• Titrate the med based on ordered parameters (BP, HR, Cardiac Index, CVP, PCWP), infusions typically range from 2 to 20 mcg/kg/min.
• Assess peripheral pulses routinely and report any decrease in peripheral perfusion.
• Labs: monitor potassium levels; anticipate hypokalemia. Other labs: renal panel, electrolytes, lactate and blood glucose.
• Correct hypovolemia before initiating therapy.

Lifespan considerations

• Beta-1 agonists can safely be administered to pediatric clients, but doses must be adjusted according to weight.
• Safe to use with the older adult population, with no special dose adjustments for renal or liver insufficiency.
• Beta-1 agonists should not be given in pregnancy, if they can be avoided.

(Ashkar, et al, 2024; Vallerand & Sanoski, 2024).

Drug interactions

• Beta blockers may negate the effect of dobutamine, decreasing the inotropic effects.
• Nitroprusside may cause synergistic effect on increasing cardiac output.
• Dobutamine with anesthetic agents can lead to arrythmias (Vallerand & Sanoski, 2024).

Adverse/Side effects

• Can cause a marked increase in heart rate and blood pressure.
• Risk of ectopy and arrythmias
• Report all adverse reactions promptly, especially laboured breathing, angina, palpitations, and dizziness.

Client Teaching

The client should be instructed to inform the nurse immediately if they notice chest pain, shortness of breath, or numbness or tingling in the extremities (Vallerand & Sanoski, 2024).

Dobutamine Medication Card

Now let’s take a closer look at the medication card for dobutamine (UpToDate, 2021, Vallerand & Sanoski, 2024). Because information about medication is constantly changing, nurses should always consult evidence-based resources to review current recommendations before administering specific medication.

Downloadable file (.docx): Dobutamine Medication Card

Interactive Activity

References

• Ashkar, H., Adnan, G., Patel, P. & Makaryus, A. (2024). Dobutamine. National Library of Medicine. https://www.ncbi.nlm.nih.gov/
• uCentral from Unbound Medicine. https://www.unboundmedicine.com/ucentral ↵
• UpToDate (2021). Dobutamine. https://www.uptodate.com/contents/search ↵
• Vallerand, A. & Sanoski, C. (2024). Davis’s Canadian drug guide for nurses (19th ed.). F.A. Davis Company: Canada